The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.1M data for 1.3M Compounds and 9.6K Targets. Of those, 1.5M data for 698K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

12 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Isoform-Selective and Stereoselective Inhibition of Hypoxia Inducible Factor-2.EBI
University of Texas Southwestern Medical Center
Development of inhibitors of the PAS-B domain of the HIF-2a transcription factor.EBI
University of Texas Southwestern Medical Center
Inhibition of hypoxia inducible factor-2 transcription: isolation of active modulators from marine sponges.EBI
National Cancer Institute-Frederick
Identification and evaluation of soft coral diterpenes as inhibitors of HIF-2a induced gene expression.EBI
Nci-Frederick
Discovery of Cycloalkyl[EBI
Merck Healthcare
Discovery of a Potent and Orally Bioavailable Hypoxia-Inducible Factor 2α (HIF-2α) Agonist and Its Synergistic Therapy with Prolyl Hydroxylase Inhibitors for the Treatment of Renal Anemia.EBI
China Pharmaceutical University
Inhibitors of Hypoxia-Inducible Factors as Treatment for Cancer.EBI
Therachem Research Medilab
3-[(1EBI
Peloton Therapeutics
Design and Activity of Specific Hypoxia-Inducible Factor-2α (HIF-2α) Inhibitors for the Treatment of Clear Cell Renal Cell Carcinoma: Discovery of Clinical Candidate ( S)-3-((2,2-Difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1 H-inden-4-yl)oxy)-5-fluorobenzonitrile (PT2385).EBI
Peloton Therapeutics
PYRROLE DERIVATIVE OR PHARMACEUTICALLY OR SITOLOGICALLY ACCEPTABLE SALTS THEREOF, AND COMPOSITION FOR PREVENTION, AMELIORATION OR TREATMENT OF GASTROINTESTINAL DISORDERS COMPRISING SAME AS ACTIVE INGREDIENTBDB
Hana Pharm
Cyanopyrrolidine derivatives as inhibitors for DUBsBDB
Mission Therapeutics